Form 4: Hims & Hers CEO Andrew Dudum Exercises Options and Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc. CEO Andrew Dudum executed a series of stock option exercises and subsequent sales of Class A Common Stock on July 21, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew Dudum, CEO, Director, and 10% Owner of Hims & Hers Health, Inc. (HIMS), engaged in transactions on July 21, 2025.
• Exercised stock options to acquire a total of 125,335 shares of Class A Common Stock at an exercise price of $2.43 per share.
• Concurrently sold 125,335 shares of Class A Common Stock at weighted average prices ranging from $49.4137 to $49.5987 per share.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following these transactions, Andrew Dudum directly holds 92,313 shares of Class A Common Stock.
• Indirect beneficial ownership totals 9,993,039 shares held across various trusts, bringing total beneficial ownership to 10,085,352 shares.
• Remaining direct beneficial ownership of stock options (right to buy) totals 2,478,866 shares at an exercise price of $2.43.

Sentiment

Score: 6

Explanation: The filing reports planned insider selling by the CEO under a Rule 10b5-1 plan, which is a routine liquidity event. The CEO retains substantial direct and indirect ownership, indicating continued alignment with the company's performance. The high sale price relative to the exercise price is favorable for the insider.

Positives

• The transactions were executed at a significantly higher market price (around $49.40-$49.60) compared to the option exercise price ($2.43), indicating substantial realized gains from the options.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to immediate market conditions.
• Andrew Dudum retains substantial direct and indirect beneficial ownership, totaling over 10 million shares, demonstrating continued alignment with shareholder interests.

Negatives

• The sale of 125,335 shares by a key insider, even under a 10b5-1 plan, represents a reduction in direct holdings.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a key executive could be perceived negatively by some, but the pre-arranged nature via a 10b5-1 plan and the executive's continued significant ownership mitigate concerns. The high sale price reflects a strong stock performance.

Key Dates

Recommendation

The filing details a pre-scheduled insider transaction (option exercise and sale) by the CEO under a Rule 10b5-1 plan. This is a common liquidity event for executives and does not necessarily signal a change in the company's fundamental outlook. The CEO retains substantial beneficial ownership, indicating continued commitment. Without additional financial or strategic information, this routine transaction alone does not warrant a change from a 'hold' position, assuming the investor's existing thesis remains intact.

Keywords

Hims & Hers Health, HIMS, Andrew Dudum, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, CEO, Director, 10% Owner, Equity Transaction